Company Filing History:
Years Active: 2015-2017
Title: Anton Manuilov: Innovator in Protein Engineering
Introduction
Anton Manuilov is a notable inventor based in Burlington, MA (US). He has made significant contributions to the field of protein engineering, holding a total of 3 patents. His work focuses on optimizing the stability of binding proteins, which has important implications in biotechnology and pharmaceuticals.
Latest Patents
One of Anton's latest patents is titled "Methods for optimizing domain stability of binding proteins." This invention provides methods for measuring the inherent stability of intrachain disulphide-containing domains, such as antibody variable domains. It also outlines techniques for optimizing the positioning of these domains within proteins, particularly multispecific binding proteins like DVD-Ig molecules. The methods aim to enhance the stability of these proteins, which is crucial for their effectiveness in therapeutic applications.
Another significant patent is "Methods and systems for the analysis of protein samples." This invention relates to analyzing protein samples, including monoclonal antibodies, using the SITRS technique. It also includes methods and systems that facilitate the processing of data generated by this technique, thereby improving the efficiency of protein analysis.
Career Highlights
Anton Manuilov is currently employed at AbbVie Inc., a leading global biopharmaceutical company. His work at AbbVie focuses on advancing the development of innovative therapies through his expertise in protein engineering. His contributions have been instrumental in enhancing the stability and efficacy of therapeutic proteins.
Collaborations
Anton has collaborated with notable colleagues, including David H. Lee and Chris Chumsae. These collaborations have fostered a productive environment for innovation and have led to advancements in the field of protein engineering.
Conclusion
Anton Manuilov is a distinguished inventor whose work in optimizing binding proteins has the potential to revolutionize therapeutic applications. His patents reflect a commitment to advancing biotechnology and improving patient outcomes.